Blood-cancer medicine, manufactured in the US, won conditional approval for sale in mainland China last month.
Hutchmed weighs cancer drug’s supply-chain options amid US-China trade war
RELATED ARTICLES
Singapore jails mastermind behind US$10.9 million fake wine investment scheme
Japan probes Chinese solar panels over hidden device fears, power disruptions
China’s green energy leadership can bridge political, economic divides
